Assessment of ocular toxicity of CDK inhibitors

This is a product-capability walkthrough for Clarivate's OFF-X translational safety intelligence tool, using CDK (cyclin-dependent kinase) inhibitors as the worked example. It poses the question of whether ocular toxicity is a class effect across CDK inhibitors, whether it has appeared in marketed drugs, and whether preclinical studies anticipated the issue, using public clinical-hold disclosures. The landing page describes OFF-X's capability to evaluate such safety liabilities across CDK subtypes but does not itself contain the detailed findings; it prompts a further download for the full analysis.

The customer is anonymised in Clarivate’s own case study — not withheld by us.

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.